See our posting this week announcing the closing of our $4.2M initial financing, which positions us well to continue to advance our programs and prepare for a subsequent round of financing later this year. A special thanks to our investors and advisors, and especially our incredibly talented and committed employees, who are making this important journey possible!
We are thrilled to announce the closing of our $4.2M initial funding round. A special thanks to Safar Partners, who led this round, and our other visionary investors who appreciate the tremendous power of our unique approach. We believe that our proprietary tools leveraging the natural function of CRISPR and demystifying the virome will unlock the potential of beneficial bacterial products addressing a broad range of medical and other applications, We are excited about our progress as we embark on this next stage of our growth. For more information see https://lnkd.in/e9gFSkwZ